BRCA1 and cancer: Through rigorous validation across multiple independent cohorts, we demonstrate that MAIGGT not only achieves state‐of‐the‐art predictive performance but also provides novel insights into the spatial biology of BRCA1/2‐associated tumors, offering a transformative approach to precision cancer risk assessment.